ANI launches generic ranitidine capsules for duodenal ulcer

By Vassia Barba

- Last updated on GMT

(Image: Getty/iamnoonmai)
(Image: Getty/iamnoonmai)

Related tags ANI Pharmaceuticals Generics Generic drug Generic drugs

ANI Pharmaceuticals proceeds to commercialization of ranitidine capsules for the treatment of duodenal ulcer, through a partnership with Appco Pharma.

The drug manufacturer, based in Minnesota, US, announced the commercialisation of the drug, as the third generic product introduced by ANI since the beginning of 2019.

Ranitidine hydrochloride, an oral histamine H2-receptor antagonist, will be distributed in dosage forms of 150mg and 300mg. According to the company, the current annual US market for this product is approximately $40m (€35.2m).

The ranitidine capsules are indicated in the treatment of active duodenal ulcers, hypersecretory conditions, gastric ulcers, gastroesophageal reflux disease and erosive esophagitis.

This launch, which brings the company’s generic portfolio to 34 commercial products, was the first one to occur through ANI’s partnership with New Jersey, US-based manufacturer, Appco Pharma, which began in March 2018.

Following the announcement of the launch, ANI's CEO, Arthur Przybyl said, “We look forward to additional future launches through this partnership as we advance our collaboration.”

ANI’s targeted areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations, involving extended release and combination products.

In March 2019, the company launched methylphenidate hydrochloride extended release tablets, indicated as a treatment for attention deficit hyperactivity disorder and erythromycin ethylsuccinate for oral suspension, as a treatment for various infections.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more